/

Key to cancer’s origin found in inappropriate activation of gene

AFP-JIJI

Researchers have for the first time witnessed how a single cell can change and give rise to cancer, raising hopes that scientists may discover a way to stop tumors before they start.

Described Friday in the journal Science, the study was led by doctors at Boston Children’s Hospital and is based on zebrafish that developed melanoma.

When a cell reverted to a stem-cell state and began dividing, it became cancer, researchers found.

The spark for that change was in the crestin gene, which should only be active in embryonic tissue but became inappropriately activated again, resulting in melanoma.

“An important mystery has been why some cells in the body already have mutations seen in cancer but do not yet fully behave like the cancer,” said first author Charles Kaufman, a postdoctoral fellow in the Zon Laboratory at Boston Children’s Hospital.

“We found that the beginning of cancer occurs after activation of an oncogene or loss of a tumor suppressor, and involves a change that takes a single cell back to a stem-cell state.”

The fish contained a human cancer mutation known as BRAF V600E, which is found in most benign moles.

The fish were also engineered to have lost the tumor suppressor gene p53 and to have cells light up in fluorescent green if a gene called crestin was turned on.

“Every so often, we would see a green spot on a fish,” said co-author Dr. Leonard Zon, director of the Stem Cell Research Program at Boston Children’s. “When we followed them, they became tumors 100 percent of the time.”

The research team is trying to develop a genetic test that could be given to people with moles that may look suspicious, to see if their cells are behaving in a way that could lead to cancer.

Another avenue for study are so-called superenhancers, which turn on the genetic changes and could potentially be targeted with drugs to stop a mole from becoming cancerous.

The paper “gives us insight as to one of these additional events that can turn a benign lesion with a BRAF V600E mutation into a malignant melanoma,” said Craig Devoe, acting chief of the division of hematology and oncology at Northwell Health Cancer Institute in Lake Success, New York.

Perhaps one day, this knowledge will be translated into new therapies for patients, he added.

“There is more work to be done, but the work of Kaufman et al represents the discovery of a missing link in the transformation of benign cells into cancer,” said Devoe, who was not involved in the study.